AbbVie Acquires Aliada Therapeutics for $1.4B to Expand Alzheimer's Research Portfolio

North Chicago, IL, October 28, 2024 (Reuters) -- AbbVie will acquire Aliada Therapeutics for $1.4 billion to gain access to an early-stage Alzheimer's therapy. This acquisition reflects AbbVie's dedication to strengthening its neuroscience portfolio.  The competitive acquisition process underscores industry interest in innovative Alzheimer's treatments.

Read full article here.